Olaparib Dose Escalation in Combination With High Dose Radiotherapy to the Breast and Regional Lymph Nodes in Patients With Inoperable, Metastatic or Inflammatory Breast Cancer

Trial Profile

Olaparib Dose Escalation in Combination With High Dose Radiotherapy to the Breast and Regional Lymph Nodes in Patients With Inoperable, Metastatic or Inflammatory Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs Olaparib (Primary)
  • Indications Breast cancer; Inflammatory breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Oct 2015 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018, as reported by ClinicalTrials.gov record
    • 08 Oct 2015 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017, as reported by ClinicalTrials.gov record.
    • 01 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top